Top 10 Medical Innovations for 2009
#7 LESS and NOTES Applications
Minimally-invasive laparoscopic surgical
approaches have been tried over the years
in an effort to improve a variety of standard
urological and gynecological surgeries. We
now have two emerging innovations—LESS
and NOTES—that allow doctors to perform
surgeries with a minimum of cutting and
virtually no scars. Pain levels are significantly
reduced as well with these scarless surgeries,
allowing patients to get home and back to
activities of daily living much quicker.
Laparoscopy (from the Greek words lapara,
or flank, and skopion, a means of viewing
something) is a surgical procedure in which
small (1-2 cm) incisions are made and
plastic tubes (trocars) are inserted through
them to keep the channel open so that
tools—including surgical instruments and the
viewing telescope (laparoscope) with its minicamera—
can be inserted. When the abdomen
is inflated with carbon dioxide, organs can
be pushed out of the way for access and
better vision, allowing the surgeon to work
while watching an external video monitor. The
tools can be manipulated to make necessary
repairs, just as if the abdomen had been cut
open the old-fashioned way, but without the
surgeon’s hands ever entering the patient’s
abdomen.
LESS (laparoendoscopic single-site surgery)
takes laparoscopic surgery to an entirely new
level by reducing the process to a small cut in
the belly button. “LESS is performed through
a single incision in the patient’s navel,”
explains Inderbir S. Gill, M.D., Chairman of
Urology at the Cleveland Clinic, and a pioneer
who recently performed LESS live-donor
nephrectomies in nine consecutive kidney
donors for kidney transplantation. “All aspects
of kidney harvesting were completed though
the navel. Instead of a visible six-inch scar
and a six-week recovery period, patients
recovered within two weeks and had a tiny
scar hidden by their belly button.”
Because it only uses one port with multiple
channels for the surgeon to simultaneously
pass various surgical instruments, LESS may
also reduce complications that might occur
after traditional open and even laparoscopic
abdominal surgery. “My patients report
less discomfort and have faster recoveries
compared to those undergoing traditional
laparoscopy,” Dr. Gill says.
NOTES (natural orifice transluminal
endoscopic surgery) bypasses normal
laparoscopic incisions altogether. Instead,
the surgeon gets to an appendix, prostate,
kidney, or gallbladder through one of the
body’s natural cavities, such as the mouth,
vagina, or colon. “Being able to perform
major surgery inside the abdomen and
chest through natural orifices is a very
intriguing concept,” reports Dr. Gill. “Potential
advantages of this would be the ability to have
scar-free and, hopefully, pain-free surgery.
This is what has caught the imagination of the
public.”
Many people react with fear when given the
news about their metastatic cancer, others
with anger, and some with a sense of utter
hopelessness. When breast, colorectal,
or prostate cancer becomes metastatic,
it immediately raises numerous concerns
and important, questions. What is the best
therapy? How do I make the treatment choice?
Should I consider joining a clinical trial?
Many recurrent cancer treatment choices are
based on how the disease is progressing. To
determine this, doctors look for signs, which
are traditionally provided by imaging or tumor
marker tests at certain points during therapy.
Now there is another option: use of a new
technology to measure circulating tumor cells
(CTCs) in a sample of blood to aid in the early
detection of rogue cancer cells in patients
with recurrent cancer. This is a different
kind of test that can help people learn how
their therapy is working much sooner. The
technology allows patients to monitor their
progress at any point along their treatment
course, and guides the doctor in adjusting
therapy as needed.
CTCs are cancer cells that have broken away
from an existing tumor cell and have entered
the bloodstream. The presence of these
cells in the blood can provide valuable insight
into the progression of the cancer. Clinical
studies of patients with metastatic cancers
of the breast, colon/rectum, or prostate have
reported that the monitoring and detection of
CTCs can actually predict whether a patient’s
prognosis is more or less favorable.
This blood test captures, identifies, and
counts CTCs in a tube of blood. Using a
predetermined cutoff number—5 CTCs for
metastatic breast and prostate cancer; 3
CTCs for metastatic colorectal cancer—the
test can specifically predict a patient’s
probable outcome.
“This technology has enormous promise,”
says Daniel F. Hayes, M.D., Clinical Director
of the Breast Oncology Program at the
University of Michigan Comprehensive
Cancer Center in Ann Arbor. “I regularly use
it in my clinic. In the end, the benefit of this
technology is that it will give us a snapshot of
what cancer is doing right now without having
to biopsy the patient. That is the real hope
and excitement that this test offers.”